Gliclazide Use During Pregnancy: Is It Safe?

Gliclazide is a medication used to treat type 2 diabetes when other methods such as dietary changes, exercise, and weight loss are insufficient. While it is effective in managing blood sugar levels, concerns have been raised about its safety during pregnancy. The limited data available suggests that oral antidiabetic drugs, including gliclazide, may have adverse effects on the fetus, such as congenital abnormalities, fetal hyperinsulinemia, macrosomia, and neonatal hypoglycemia. As a result, gliclazide is generally not recommended for use during pregnancy. However, in certain cases, such as when the benefits outweigh the risks, healthcare professionals may advise its use. This decision should be made in consultation with a doctor or pharmacist, who can review the patient's treatment and suggest alternative medications if necessary.

Gliclazide is not recommended during pregnancy

Gliclazide is a medication used to treat type 2 diabetes when other methods, such as dietary changes, exercise, and weight loss, have not been effective. While this medication can be beneficial for managing blood sugar levels, it is important to note that gliclazide is not recommended for use during pregnancy. This recommendation is based on several factors and potential risks.

Firstly, there is limited information and research available regarding the safety of gliclazide during pregnancy. As a result, there is uncertainty about its potential effects on the developing fetus. The lack of sufficient data makes it difficult to conclusively determine whether gliclazide poses any risks to the pregnancy or the health of the fetus.

Additionally, gliclazide belongs to the sulfonylurea family of medications, and the use of this class of drugs during pregnancy is generally not advised. Sulfonylureas can cross the placenta and have been associated with neonatal adverse reactions, such as hypoglycemia. This can lead to severe health complications for the newborn infant.

Furthermore, oral antidiabetic medications, including gliclazide, are not recommended during pregnancy due to their known effects on the fetus. These effects can include congenital abnormalities, fetal hyperinsulinemia, macrosomia, and neonatal hypoglycemia. While there have been isolated cases of women who continued gliclazide during pregnancy and delivered healthy babies, these instances do not provide sufficient evidence to conclude that gliclazide is safe for use during pregnancy.

It is important for women who are pregnant or planning to become pregnant to consult their doctor or pharmacist before taking gliclazide. Healthcare professionals can review their treatment plan and suggest alternative medications that are safer for use during pregnancy, such as insulin or metformin. The health and safety of both the mother and the fetus are paramount, and any potential risks associated with gliclazide use during pregnancy must be carefully considered and mitigated.

Insulin is recommended during pregnancy

Insulin is the recommended treatment for diabetes during pregnancy. This is because insulin helps to maintain blood glucose levels as normal as possible, reducing the risk of harm to the foetus and mother.

Insulin requirements may change during pregnancy, and the optimal treatment for pre-existing diabetes is unclear. There are several insulin regimens (e.g. via syringe, pen) and types of insulin (e.g. fast-acting insulin, human insulin). Insulin is a hormone made naturally in the body by pancreatic beta cells. This hormone controls the level of glucose in the blood.

There are different types of insulin available, which are classified according to how quickly and for how long they work on various parts of the body. There are also many different methods of administering insulin, referred to as 'regimens'.

Insulin therapy remains the standard of care for type 1 diabetes, type 2 diabetes, and uncontrolled gestational diabetes during pregnancy. Regular insulin, insulin aspart, insulin lispro, and NPH have the most human pregnancy data. Insulin detemir is quickly gaining data and provides an additional option for basal coverage.

As we move into a new era of insulin technology, patients may be on insulin that has no human data for pregnant patients prior to becoming pregnant. Accurately assessing the risks and benefits of changing insulin therapy will become a crucial role for clinicians. Furthermore, sharing the analysis with the patient to include her in determining the best insulin regimen is essential. Regardless of the regimen chosen, tight glycemic control throughout pregnancy is essential for the best fetal outcomes.

Gliclazide may cause neonatal hypoglycaemia

Gliclazide is a medicine used to treat diabetes. It is not recommended for use during pregnancy due to limited information about its safety. While there is no clear evidence of drug-associated risks for major birth defects, miscarriage, or adverse maternal outcomes, gliclazide crosses the placenta and has been linked to neonatal adverse reactions, particularly neonatal hypoglycaemia.

Neonatal hypoglycaemia, or low blood sugar in newborn babies, occurs when an infant's blood glucose level falls below the normal range. This condition can be fatal if left untreated, and it is the most common metabolic issue in newborns. The risk of neonatal hypoglycaemia is higher in infants of diabetic mothers, and it is often observed in premature and small babies.

Gliclazide can cause hypoglycaemia, or a "hypo", as a side effect. This occurs when your blood sugar drops too low. While gliclazide-induced hypoglycaemia typically occurs in diabetic patients, it is possible that it could also affect pregnant women and their infants.

Pregnant women taking gliclazide may experience hypoglycaemia if they take too high a dose, eat meals irregularly, or skip meals. Additionally, not maintaining a healthy diet, excessive exercise without sufficient carbohydrate intake, alcohol consumption, and certain medical conditions can also contribute to hypoglycaemia.

If a pregnant woman taking gliclazide experiences hypoglycaemia, it could potentially affect the infant and lead to neonatal hypoglycaemia. Therefore, it is crucial for pregnant women taking gliclazide to closely monitor their blood sugar levels and maintain a consistent and nutritious diet to minimise the risk of hypoglycaemia for both themselves and their unborn child.

Gliclazide crosses the placenta

Gliclazide is an anti-diabetic medication used to treat type 2 diabetes. It is not recommended for use during pregnancy as there is limited information about its safety during this time. Insulin and metformin are typically recommended for managing diabetes in pregnant people.

Gliclazide is classified as a sulfonylurea, a type of drug that increases insulin release. It is important to note that sulfonylureas, in general, are not recommended for use during pregnancy due to potential risks to the fetus, such as congenital abnormalities, fetal hyperinsulinemia, macrosomia, and neonatal hypoglycemia. While there have been isolated cases of healthy pregnancies while taking gliclazide, this does not indicate that the drug is safe for use during gestation.

In summary, while gliclazide may be an effective treatment for type 2 diabetes outside of pregnancy, its use during pregnancy is not recommended due to insufficient safety data and potential risks to the fetus and newborn. Alternative treatments, such as insulin or metformin, are typically advised for managing diabetes during pregnancy to ensure the safety of both the mother and the developing child.

Gliclazide is not recommended during breastfeeding

Gliclazide is not usually recommended while breastfeeding. Although it is only likely to be a small amount, it is unknown how much gliclazide passes into breast milk. This uncertainty, coupled with the drug's potential to lower an infant's blood sugar level, means that it is not considered safe for breastfeeding mothers to take gliclazide.

If a breastfeeding mother is taking gliclazide, it is important to monitor the infant for any signs of hypoglycaemia, such as unusual sleepiness or restlessness, and to seek medical advice if any concerns arise. In such cases, a doctor may suggest alternative medication or advise the mother to discontinue breastfeeding.

It is important to note that insulin is generally recommended during pregnancy to maintain normal blood glucose levels. However, if gliclazide is taken during pregnancy, it should be discontinued a few weeks before the expected delivery date.

Breastfeeding mothers should always consult their doctor or pharmacist before taking any medication, as they can advise on the best course of action and suggest alternative treatments if necessary.

Frequently asked questions